Coherus has divested Yusimry under an asset purchase agreement to Hong Kong King-Friend Industry (HKF) granting it global rights & all relevant assets of Yusimry such as its development & regulatory outcomes for $40M upfront
HKF has further granted the US commercial rights of the asset to Meitheal Pharmaceuticals (its subsidiary) under an exclusive license & supply agreement. Both the agreements will be effective, pending standard conditions & approvals
Meitheal will develop pediatric presentations & a high-concentration (100mg/mL) formulation of Yusimry (available in prefilled syringe & autoinjector forms), with its approvals in other indications & formulation anticipated in 2025
Ref: Businesswire | Image: Coherus
Related News:- Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
